GlassScriptPhysician profile
Allen Austin
NPI 1386638476
$62,346.81
in general payments reported to CMS, 2019-2025
23 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $337 · 2021: $2,182 · 2022: $8,094 · 2023: $6,682 · 2024: $29K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $19K · Consulting Fee: $2,800 · Travel and Lodging: $2,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,300.00 |
| Food and Beverage | $18,844.36 |
| Consulting Fee | $2,800.00 |
| Travel and Lodging | $2,522.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $28,445.38 | 2024-2025 | Xdemvy |
| Lumenis Be INC | $24,441.18 | 2021-2025 | Optilight, M22 |
| Visioneering Technologies, INC. | $4,372.82 | 2024 | |
| Oyster Point Pharma, INC. | $1,280.04 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $1,162.89 | 2020-2025 | Cequa |
| Sight Sciences, INC. | $471.79 | 2020-2022 | |
| Harrow Eye, LLC | $328.97 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $288.66 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $252.67 | 2024-2025 | Tryptyr, Precision 1, Dailies Total1 |
| Ani Pharmaceuticals, INC. | $220.29 | 2024-2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.96 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $211.17 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Dompe US, INC. | $142.80 | 2022-2025 | Oxervate |
| Lumenis, INC | $122.54 | 2021 | |
| Shire North American Group INC | $114.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionix USA, INC | $78.31 | 2022 | |
| Glaukos Corporation | $38.68 | 2021-2025 | Idosetr, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $38.00 | 2020 | |
| Allergan, INC. | $29.47 | 2021 | |
| Tearlab Corp | $24.87 | 2023 | Tearlab Osmolarity System |
| Novartis Pharmaceuticals Corporation | $23.18 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.80 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.